Bristol-Myers Squibb Company (NYSE:BMY) ranks among the most active blue chip stocks to buy now. On January 7, UBS upgraded ...

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. Bristol-Myers Squibb Company is placed second among the ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

Share price of Bristol Myers Squibb (BMY) touched a 52-week low of $42.96 on July 31, post its second-quarter earnings release. The stock has recovered 6.7% since then and is currently trading at ...

Bristol Myers Squibb Company BMY has delivered a solid performance in recent months. The biotech major’s shares have gained ...

Bristol Myers Squibb (BMY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Bristol Myers Squibb remains significantly undervalued, trading at a forward P/E of 8x, versus the sector median of 19.5x. BMY's growth portfolio now generates 57% of total revenue, growing 18% YoY ...

At first glance, Bristol-Myers Squibb appears cheap with a low P/E and strong dividend yield. GAAP earnings are consistently much lower than non-GAAP figures, reflecting costs which may limit cash ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the Best Beaten Down Stocks to Buy According to Hedge Funds. On October 10, Citi lifted the price target on the company’s stock to $48 from $47, while ...